Skip to main content
رجوع
ABBV logo

AbbVie Inc.

جودة البيانات: 100%
ذروة بيع
ABBV
NYSE Healthcare Drug Manufacturers - General
KWD 205.12
▲ KWD 0.19 (0.09%)
القيمة السوقية: 362.69B
نطاق اليوم
KWD 201.80 KWD 206.01
نطاق 52 أسبوعًا
KWD 164.39 KWD 244.81
حجم التداول
6,972,423
متوسط 50 يوم / 200 يوم
KWD 223.12 / KWD 215.25
الإغلاق السابق
KWD 204.93

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 85.8 0.3
P/B 2.9
ROE % 15367.3 3.7
Net Margin % 6.9 3.8
Rev Growth 5Y % 2.1 10.0
D/E 0.2

السعر المستهدف للمحللين

Hold
KWD 256.150 +24.9%
Low: KWD 223.000 High: KWD 299.000
مكرر الربحية المستقبلي
14.1
ربحية السهم المستقبلية
KWD 14.569
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
67 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 20.054
KWD 19.564 – KWD 20.397
84 B 5
FY2029 KWD 19.551
KWD 19.073 – KWD 19.886
82 B 10
FY2028 KWD 17.867
KWD 13.135 – KWD 21.128
78 B 12

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Feb 27, 2026
Michael Robert A.
CHAIRMAN OF THE BOARD AND CEO
other 36,523 KWD 232.080 KWD 8,476,258
Feb 27, 2026
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
other 21,638 KWD 232.080 KWD 5,021,747
Feb 27, 2026
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
other 12,874 KWD 232.080 KWD 2,987,798
Feb 27, 2026
Purdue David Ryan
SVP, Controller
other 2,692 KWD 232.080 KWD 624,759
Feb 27, 2026
Thakkar Roopal
EVP, R&D and CSO
other 8,037 KWD 232.080 KWD 1,865,227
Feb 27, 2026
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
other 16,309 KWD 232.080 KWD 3,784,993
Dec 31, 2025
Quaggin Susan E
grant 68 KWD 228.490 KWD 15,537
Sep 30, 2025
RAPP EDWARD J
grant 145 KWD 231.540 KWD 33,573
Sep 30, 2025
Quaggin Susan E
grant 67 KWD 231.540 KWD 15,513
Jun 30, 2025
Quaggin Susan E
grant 81 KWD 185.620 KWD 15,035
Jun 30, 2025
Alpern Robert J
grant 40 KWD 185.620 KWD 7,425
May 9, 2025
Davis Jennifer L.
grant 1,203
May 9, 2025
Alpern Robert J
grant 1,203
May 9, 2025
Quaggin Susan E
grant 1,203
May 9, 2025
Hart Brett J
grant 1,203
May 9, 2025
AUSTIN ROXANNE S
grant 1,203
May 9, 2025
RAPP EDWARD J
grant 1,203
May 9, 2025
WADDELL FREDERICK H
grant 1,203
Mar 31, 2025
GONZALEZ RICHARD A
other 2,450
Mar 31, 2025
RAPP EDWARD J
grant 155 KWD 209.520 KWD 32,476

النقاط الرئيسية

Revenue grew 2.14% annually over 5 years — modest growth
ROE of 15367.27% indicates high profitability
Generating 17.82B in free cash flow
P/E of 85.82 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.43%
Cash machine — converts 421.58% of earnings into free cash flow

النمو

Revenue Growth (5Y)
2.14%
Revenue (1Y)8.57%
Earnings (1Y)-1.22%
FCF Growth (3Y)-10.14%

الجودة

Return on Equity
15367.27%
ROIC24.18%
Net Margin6.91%
Op. Margin34.69%

الأمان

Debt / Equity
N/A
Current Ratio0.67
Interest Coverage8.08

التقييم

P/E Ratio
85.82
P/B RatioN/A
EV/EBITDA20.11
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.57% Revenue Growth (3Y) 6.11%
Earnings Growth (1Y) -1.22% Earnings Growth (3Y) -6.78%
Revenue Growth (5Y) 2.14% Earnings Growth (5Y) -22.21%
Profitability
Revenue (TTM) 61.16B Net Income (TTM) 4.23B
ROE 15367.27% ROA 3.15%
Gross Margin 83.71% Operating Margin 34.69%
Net Margin 6.91% Free Cash Flow (TTM) 17.82B
ROIC 24.18% FCF Growth (3Y) -10.14%
Safety
Debt / Equity N/A Current Ratio 0.67
Interest Coverage 8.08 Dividend Yield 0.03%
Valuation
P/E Ratio 85.82 P/B Ratio N/A
P/S Ratio 5.93 PEG Ratio -116.18
EV/EBITDA 20.11 Dividend Yield 0.03%
Market Cap 362.69B Enterprise Value 426.53B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 61.16B 56.33B 54.32B 58.05B 56.20B
Net Income 4.23B 4.28B 4.86B 11.84B 11.54B
EPS (Diluted) 2.36 2.39 2.72 6.63 6.45
Gross Profit 51.20B 39.43B 33.90B 40.64B 38.75B
Operating Income 21.21B 9.14B 12.76B 18.12B 17.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 133.96B 135.16B 134.71B 138.81B 146.53B
Total Liabilities 137.19B 131.80B 124.31B 121.52B 131.09B
Shareholders' Equity -3.27B 3.33B 10.36B 17.25B 15.41B
Total Debt 69.07B 67.84B 60.12B 64.19B 77.58B
Cash & Equivalents 5.23B 5.52B 12.81B 9.20B 9.75B
Current Assets 29.06B 25.58B 33.00B 28.46B 27.93B
Current Liabilities 43.29B 38.75B 37.84B 29.54B 35.19B